NEUVÉ Review

What NEUVÉ charges

• Sermorelin: $184/mo — "starting at" per month, and the seller's own pricing answer says "Medication, labs, and treatment supplies are billed separately" — so the drug is not in this figure
• NAD+: $217/mo — "starting at" per month, and the seller's own pricing answer says "Medication, labs, and treatment supplies are billed separately" — so the drug is not in this figure
• Glutathione: $142/mo — "starting at" per month, and the seller's own pricing answer says "Medication, labs, and treatment supplies are billed separately" — so the drug is not in this figure
• Tesamorelin: $225/mo — "starting at" per month, and the seller's own pricing answer says "Medication, labs, and treatment supplies are billed separately" — so the drug is not in this figure
• BPC-157: $269/mo — the seller's "BPC-157 + TB-500" stack, "starting at" per month — one figure for two peptides, and its pricing answer says "Medication, labs, and treatment supplies are billed separately"
• CJC-1295: $265/mo — the seller's "CJC-1295 + Ipamorelin" stack, "starting at" per month — one figure for two peptides, and its pricing answer says "Medication, labs, and treatment supplies are billed separately"

NEUVÉ also sells 2 compounds this site boards without publishing a price for them: TB-500 (board ranks no provider) and Ipamorelin (board ranks no provider).

The figure on the page is not the price of the therapy

Each protocol page carries a number and the words per month, starting at. Read on its own, that is the shape of a program price, and it sits where a program price would sit.

The seller answers its own question about this on its home page. Asked what is included in the monthly price, it says monthly prices start at consultation, titration support and standard shipping where applicable, and that medication, labs and treatment supplies are billed separately by an independent clinical partner.

The medication is the largest part of what a compounded peptide program costs, and it is outside the figure. Its terms repeat the point, saying medication, laboratory testing and clinical treatment charges are billed directly by the applicable independent provider rather than by the company.

This site records the published figures because they are published, and every one of its price rows says in the qualifier that the drug is not in them. The real cost of any of these protocols is higher than the number stored, and no attempt is made here to guess how much higher.

Six protocols, and two of them are stacks

Sermorelin, NAD+, glutathione and tesamorelin each have a protocol page and a figure of their own. Four of the six compounds this site ranks are reachable here.

The other two protocol pages price a pair rather than a peptide. One sells BPC-157 together with TB-500 at a single figure; the other sells CJC-1295 together with ipamorelin at a single figure. Neither peptide in either pair is offered or priced on its own.

Each stack figure is recorded once, against the peptide the seller names first in its own product title, with the pairing spelled out in the qualifier. It is deliberately not repeated against the second peptide in the pair: one price standing on two boards would make this seller look twice as cheap as it is.

Every one of the six figures is a floor rather than a rate. Each is published as a starting figure with no plan term, no tier table and no ceiling, so a reader cannot tell from the page what a typical month comes to even before the medication is added.

The labs are named, and the pharmacy is not

This seller names the laboratories it draws through, telling a reader that samples are taken at a partner site near them and naming the two national laboratory networks by name. That is a concrete, checkable disclosure, and most of this roster offers nothing equivalent about its lab arrangements.

The pharmacy gets no such treatment. The site describes medication as compounded by a United States pharmacy of a particular regulatory class, and as shipped from licensed pharmacies, and never names one. Eight of the thirty-one sellers compared here name the facility that fills an order; this is one of the twenty-three that do not.

Lab costs are excluded from the monthly figure in the same sentence that excludes the medication, so a reader budgeting for this program is looking at three separate charges rather than one.

None of these six protocols is an FDA-approved finished drug. The site is direct about this on the BPC-157 page, saying the compound is available through licensed compounding pharmacies when prescribed for an individual patient, is not sold as an FDA-approved finished product, and is banned in most tested sport.

Fifty states, forty-plus states, and which is which

The site's own question about coverage is answered with all fifty states, and it says care is delivered by clinicians licensed in a patient's state of residence. Twelve of the thirty-one sellers here make an all-fifty claim.

The same home page also says, in four separate places, that it has members in more than forty states. Those two statements are not actually in conflict: one is about where clinicians hold licenses and the other is about where members currently live, and a company can honestly be licensed in more states than it has customers.

This site records the fifty-state answer and flags the softer line rather than treating it as a contradiction it is not. What is missing from both is a list, so a reader still cannot check a specific state in advance.

The operating company is named in the terms as a limited liability company in Gilbert, Arizona, with Arizona law governing and disputes venued in Maricopa County. That is a clearer legal answer than several sellers here provide.

How we verified this

• Loaded all six protocol pages twice, more than a minute apart, and compared the price and term tokens; all six were identical across the pair.
• Probed the host with a nonsense path in the same run and confirmed a not-found response, so a success on these pages means a real page.
• Extracted every page byte-safely rather than with a text search tool, because these pages carry null bytes that make a naive search report nothing at all.
• Read the home page pricing answer in full and recorded the exclusion sentence verbatim into every price row rather than summarizing it once and hoping a reader finds it.
• Confirmed the same exclusion independently in the terms, so the finding does not rest on a single accordion answer.
• Recorded each stack figure once, against the peptide the seller names first, and deliberately did not repeat it against the second peptide in the pair.
• Separated the fifty-state licensure answer from the forty-plus-states membership line instead of reporting them as a contradiction.
• Searched all six protocol pages and the terms for a named pharmacy and found only a regulatory class.
• Counted the pharmacy-naming and all-fifty claims against the current roster rather than reusing an earlier figure.